Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CCR2 | P41597 | 4/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.45 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776872 | 1.00 | HTT (0.53) | HTTSMN1; SMN2MEN1LMNARECQL | |
| SCHEMBL1776874 | 1.00 | HTT (0.53) | HTTSMN1; SMN2MEN1LMNARECQL | |
| SCHEMBL1780257 | 0.86 | CCR2 (0.70) | HTTSMN1; SMN2MEN1LMNARECQL | |
| SCHEMBL1778669 | 0.84 | KCNH2 (0.54) | HTTSMN1; SMN2MEN1LMNARECQL | |
| SCHEMBL4650399 | 0.84 | KCNH2 (0.54) | HTTSMN1; SMN2MEN1LMNARECQL | |
| SCHEMBL1778303 | 0.84 | CCR2 (0.53) | HTTSMN1; SMN2MEN1LMNARECQL | |
| SCHEMBL1779007 | 0.84 | CCR2 (0.53) | HTTSMN1; SMN2MEN1LMNARECQL | |
| SCHEMBL14495618 | 0.84 | CCR2 (0.49) | HTTSMN1; SMN2MEN1LMNARECQL | |
| SCHEMBL1777761 | 0.83 | CCR2 (0.55) | HTTSMN1; SMN2MEN1LMNARECQL | |
| SCHEMBL1777896 | 0.82 | CCR2 (0.52) | HTTSMN1; SMN2MEN1LMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1966187-A1 | PIPERAZINE COMPOUNDS USEFUL AS ANTAGONISTS OF C-C CHEMOKINES (CCR2B AND CCR5) FOR THE TREATMENT OF INFLAMMATORY DISEASES | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071952-A1 | PIPERAZINE COMPOUNDS USEFUL AS ANTAGONISTS OF C-C CHEMOKINES (CCR2B AND CCR5) FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071952-A1 | PIPERAZINE COMPOUNDS USEFUL AS ANTAGONISTS OF C-C CHEMOKINES (CCR2B AND CCR5) FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | CCR2, CCR5, CCL2 | HTT 4706/4885SMN1; SMN2 4257/4885MEN1 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.